AGP Executive Report
Last update: an hour agoCOVID-19 Vaccine Update: The European Commission has authorized Pfizer-BioNTech’s 2026–2027 COVID-19 vaccine adapted to the XFG variant for people aged 6 months and older, with approval valid across EU member states plus Iceland, Liechtenstein, and Norway. Pharma Access & Costs: A branded drug tariff change is set to reshape US pricing and supply for major companies, while generics face a separate multi-year tariff timeline. Cardiovascular Drug Pipeline: NewAmsterdam Pharma and Menarini received a positive CHMP opinion for Ubeslo® (obicetrapib) and Evlarco® (obicetrapib plus ezetimibe) aimed at lowering LDL-C in primary hypercholesterolemia, with an EU decision expected in 2H26. Medtech Funding in the Region: Healthcare Holding Schweiz AG closed CHF 80 million in syndicated financing to expand its independent medtech distribution and acquisition strategy, with Liechtenstein’s Landesbank among the lenders. Disability Benefits Reminder: The UK DWP warns PIP recipients that leaving the country for more than four weeks can trigger penalties unless they notify the agency. Work & Health Tech Careers: The UK Met Office is hiring junior software developers to support weather and climate services.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
